Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder
Background Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce. Case Presentation In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy. Conclusion The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
基金：
National Natural Science Foundation of China [81600120, 81570197]
第一作者单位：[1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Hematol,Wuhan,Peoples R China
通讯作者：
通讯机构：[1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Hematol,Wuhan,Peoples R China[2]Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Peoples R China
推荐引用方式(GB/T 7714)：
Yan Nan,Wang Na,Zhang Peiling,et al.Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.709370.
APA：
Yan, Nan,Wang, Na,Zhang, Peiling,Wang, Gaoxiang,Mao, Xia...&Cao, Yang.(2021).Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder.FRONTIERS IN ONCOLOGY,11,
MLA：
Yan, Nan,et al."Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder".FRONTIERS IN ONCOLOGY 11.(2021)
